Experiment 1218979

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationANON:. (1990). HYPERICIN SYMPTOMATIC ARC STUDY PROTOCOL; PHASE I/II DOSE RANGING TRIAL.. 4(2)
Amount utilized
Compound isolated
DiseaseTHIS IS A NOTICE FOR A PLANNED CLINICAL TRIAL OF HYPERICIN IN 60 PATIENTS WITH ARC, STARTING DECEMBER, 1989. DOSING FREQUENCY WILL BE 250 MG 3 TIMES DAILY, 500 MG 3 TIMES DAILY AND 750 MG 3 TIMES DAILY FOR 2 MONTHS. THE STUDY SITE WILL BE THE COMMUNITY RESEARCH INITIATIVE, NEW YORK. EXCLUSION CRITERIA: LYMPHOMA, HYPERICIN WITHIN 3 MONTHS OF ENTRY AND CONCURRENT ANTIDEPRESSANTS, DEMEROL OR AMPHETAMINES. INCLUSION CRITERIA: PLATELETS GREATER THAN 50,000, SGOT/PT GREATER THAN 3 TIMES NORMAL, CREATININE LESS THAN 2.0, GRANULOCYTES GREATER THAN 750, AGE GREATER THAN 12.
Dose amount250.0 MG
Number1
Qualitative result.
AnimalHUMAN ADULT
Per unitPERSON
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES